{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:46:36Z","timestamp":1787161596525,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hypothalamic obesity (HO) in children has severe health consequences. Lifestyle interventions are mostly insufficient and currently no drug treatment is approved for children with HO. Amphetamines are known for their stimulant side-effect on resting energy expenditure (REE) and suppressing of appetite. Earlier case series have shown positive effects of amphetamines on weight in children with acquired HO. We present our experiences with dextroamphetamine treatment in the, up to now, largest cohort of children with HO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort evaluation was performed of children with HO treated with dextroamphetamine at two academic endocrine pediatric clinics. Off-label use of dextroamphetamine was initiated in patients with progressive, therapy-resistant acquired or congenital HO. Anthropometrics, REE, self-reported (hyperphagic) behavior and energy level, and side effects were assessed at start and during treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nineteen patients with a mean age of 12.3 \u00b1 4.0 years had been treated with dextroamphetamine. In two patients, \u0394BMI SDS could not be evaluated due to short treatment duration or the simultaneous start of extensive lifestyle treatment. Mean treatment duration of the 17 evaluated patients was 23.7 \u00b1 12.7 months. Fourteen patients (\n                      <jats:italic>n<\/jats:italic>\n                      = 10 with acquired HO,\n                      <jats:italic>n<\/jats:italic>\n                      = 4 with congenital HO) responded by BMI decline or BMI stabilization (mean \u0394BMI SDS of -0.6 \u00b1 0.8, after a mean period of 22.4 \u00b1 10.5 months). In three patients, BMI SDS increased (mean \u0394BMI SDS of +0.5 \u00b1 0.1, after a mean period of 29.7 \u00b1 22.6 months). In 11 responders, measured REE divided by predicted REE increased with +8.9%. Thirteen patients (68.4%) reported decreased hyperphagia, improvement of energy level and\/or behavior during treatment. Two patients developed hypertension during treatment, which resulted in dosage adjustment or discontinuation of treatment. Twelve children continued treatment at last moment of follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In addition to supportive lifestyle interventions, dextroamphetamine treatment may improve BMI in children with HO. Furthermore, dextroamphetamines have the potential to decrease hyperphagia and improve resting energy expenditure, behavior, and energy level. In patients with acquired HO, these effects seem to be more pronounced when compared to patients with congenital HO. Future studies are needed to support these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2022.845937","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T01:54:14Z","timestamp":1646790854000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Dextroamphetamine Treatment in Children With Hypothalamic Obesity"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiska","family":"van Schaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila S.","family":"Welling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corjan J.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith P.","family":"van Eck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Juriaans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Burghard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastianus B. J.","family":"Oude Ophuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J. E.","family":"Tissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette Y. N.","family":"Schouten-van Meeteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L. T.","family":"van den Akker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke M.","family":"van Santen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1210\/er.2018-00017","article-title":"Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review","volume":"40","author":"van Iersel","year":"2019","journal-title":"Endocr Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021797","article-title":"Obesity in Patients With Craniopharyngioma: Assessment of Food Intake and Movement Counts Indicating Physical Activity","volume":"88","author":"Harz","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2015-0167","article-title":"Comparison of Energy Expenditure, Body Composition, Metabolic Disorders, and Energy Intake Between Obese Children With a History of Craniopharyngioma and Children With Multifactorial Obesity","volume":"28","author":"Bomer","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2014-0512","article-title":"Hypothalamic Obesity in Children: Pathophysiology to Clinical Management","volume":"28","author":"Haliloglu","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0993","article-title":"Reduced Energy Expenditure and Impaired Feeding-Related Signals But Not High Energy Intake Reinforces Hypothalamic Obesity in Adults With Childhood Onset Craniopharyngioma","volume":"95","author":"Holmer","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tics.2010.11.001","article-title":"Reward, Dopamine and the Control of Food Intake: Implications for Obesity","volume":"15","author":"Volkow","year":"2011","journal-title":"Trends Cognit Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3525","article-title":"Excess Mortality and Morbidity in Patients With Craniopharyngioma, Especially in Patients With Childhood Onset: A Population-Based Study in Sweden","volume":"100","author":"Olsson","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1489-9","article-title":"Quality of Life and Growth After Childhood Craniopharyngioma: Results of the Multinational Trial KRANIOPHARYNGEOM 2007","volume":"59","author":"Heinks","year":"2018","journal-title":"Endocrine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3382\/ps.0581619","article-title":"The Hypothalamus and the Regulation of Food Intake","volume":"58","author":"Smith","year":"1979","journal-title":"Poult Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"764017","DOI":"10.1155\/2012\/764017","article-title":"The Use of Functional MRI to Study Appetite Control in the CNS","volume":"2012","author":"De Silva","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fnsys.2015.00090","article-title":"Lateral Hypothalamus, Nucleus Accumbens, and Ventral Pallidum Roles in Eating and Hunger: Interactions Between Homeostatic and Reward Circuitry","volume":"9","author":"Castro","year":"2015","journal-title":"Front Syst Neurosci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2014.03.003","article-title":"The Hypothalamic Arcuate Nucleus and the Control of Peripheral Substrates","volume":"28","author":"Joly-Amado","year":"2014","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2005.10.007","article-title":"The Rise, Fall, and Resurrection of the Ventromedial Hypothalamus in the Regulation of Feeding Behavior and Body Weight","volume":"87","author":"King","year":"2006","journal-title":"Physiol Behav"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.026609","article-title":"Hypothalamic Circuits Regulating Appetite and Energy Homeostasis: Pathways to Obesity","volume":"10","author":"Timper","year":"2017","journal-title":"Dis Model Mech"},{"key":"B15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/14737175.2018.1528874","article-title":"Childhood-Onset Craniopharyngioma: Latest Insights Into Pathology, Diagnostics, Treatment, and Follow-Up","volume":"18","author":"Bogusz","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1946.26.4.541","article-title":"Mechanism of the Development of Obesity in Animals With Hypothalamic Lesions","volume":"26","author":"Brobeck","year":"1946","journal-title":"Physiol Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81865-6","article-title":"Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice","volume":"88","author":"Huszar","year":"1997","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/32911","article-title":"A Mutation in the Human Leptin Receptor Gene Causes Obesity and Pituitary Dysfunction","volume":"392","author":"Clement","year":"1998","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2010.168","article-title":"Childhood Craniopharyngioma\u2013Current Concepts in Diagnosis, Therapy and Follow-Up","volume":"6","author":"Muller","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12771","article-title":"Weight Management in Obesity - Past and Present","volume":"70","author":"Haslam","year":"2016","journal-title":"Int J Clin Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative Efficacy and Tolerability of Medications for Attention-Deficit Hyperactivity Disorder in Children, Adolescents, and Adults: A Systematic Review and Network Meta-Analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2005.04.003","article-title":"Mechanisms of Neurotransmitter Release by Amphetamines: A Review","volume":"75","author":"Sulzer","year":"2005","journal-title":"Prog Neurobiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114531664","article-title":"Dopamine D2\/3 Receptor Availability and Amphetamine-Induced Dopamine Release in Obesity","volume":"28","author":"van de Giessen","year":"2014","journal-title":"J Psychopharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2015.00014","article-title":"Piloting a New Approach to the Treatment of Obesity Using Dexamphetamine","volume":"6","author":"Poulton","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2008.165464","article-title":"Exercise and Adrenaline Increase PGC-1{Alpha} mRNA Expression in Rat Adipose Tissue","volume":"587","author":"Sutherland","year":"2009","journal-title":"J Physiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.156.9.887","article-title":"The Use of Dextroamphetamine to Treat Obesity and Hyperphagia in Children Treated for Craniopharyngioma","volume":"156","author":"Mason","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2006.19.2.129","article-title":"Dexamphetamine Use for Management of Obesity and Hypersomnolence Following Hypothalamic Injury","volume":"19","author":"Ismail","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000495851","article-title":"Treatment of Hypothalamic Obesity With Dextroamphetamine: A Case Series","volume":"12","author":"Denzer","year":"2019","journal-title":"Obes Facts"},{"key":"B29","first-page":"5","article-title":"Predicting Basal Metabolic Rate, New Standards and Review of Previous Work","author":"Schofield","year":"1985","journal-title":"Hum Nutr Clin Nutr"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e27608","DOI":"10.1371\/journal.pone.0027608","article-title":"Increase in Prevalence of Overweight in Dutch Children and Adolescents: A Comparison of Nationwide Growth Studies in 1980, 1997 and 2009","volume":"6","author":"Schonbeck","year":"2011","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/030144699282999","article-title":"Centiles of Body Mass Index for Dutch Children Aged 0-20 Years in 1980\u2013a Baseline to Assess Recent Trends in Obesity","volume":"26","author":"Cole","year":"1999","journal-title":"Ann Hum Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000509302","article-title":"Experiences With Glucagon-Like Peptide-1 Receptor Agonist in Children With Acquired Hypothalamic Obesity","volume":"13","author":"van Schaik","year":"2020","journal-title":"Obes Facts"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e12577","DOI":"10.1111\/ijpo.12577","article-title":"Methylphenidate in Children With Monogenic Obesity Due to LEPR or MC4R Deficiency Improves Feeling of Satiety and Reduces BMI-SDS-A Case Series","volume":"15","author":"Brandt","year":"2020","journal-title":"Pediatr Obes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.12.023","article-title":"Successful Methylphenidate Treatment of Early Onset Extreme Obesity in a Child With a Melanocortin-4 Receptor Gene Mutation and Attention Deficit\/Hyperactivity Disorder","volume":"660","author":"Albayrak","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2013.00036","article-title":"Serotonin and the Regulation of Mammalian Energy Balance","volume":"7","author":"Donovan","year":"2013","journal-title":"Front Neurosci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e13210","DOI":"10.1111\/obr.13210","article-title":"Serotonin, Food Intake, and Obesity","volume":"22","author":"van Galen","year":"2021","journal-title":"Obes Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the Once-Daily GLP-1 Analog Liraglutide on Gastric Emptying, Glycemic Parameters, Appetite and Energy Metabolism in Obese, Non-Diabetic Adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e12481","DOI":"10.1111\/cob.12481","article-title":"Effects of Glucagon-Like Peptide-1 Analogue Treatment in Genetic Obesity: A Case Series","volume":"11","author":"Welling","year":"2021","journal-title":"Clin Obes"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.014803","article-title":"Anti-Obesity Therapy: From Rainbow Pills to Polyagonists","volume":"70","author":"Muller","year":"2018","journal-title":"Pharmacol Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200822030-00003","article-title":"Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder: Epidemiology, Prevention and Management","volume":"22","author":"Graham","year":"2008","journal-title":"CNS Drugs"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.845937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T01:54:16Z","timestamp":1646790856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.845937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":41,"alternative-id":["10.3389\/fendo.2022.845937"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.845937","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"article-number":"845937"}}